Home About ATSDR Press Room A-Z Index Glossary Employment Training Contact Us CDC  
ATSDR/DHHS Agency for Toxic Substances and Disease Registry Agency for Toxic Substances and Disease Registry Department of Health and Human Services ATSDR en Español

Search:

Section Contents
 
Learning Objectives
Diazepam for Seizures
Indications
Dose
Key Points
Progress Check
 
Case Contents
 
Table of Contents
Cover Page
How to Use the Course
Initial Check
Mass Casualty Events
Cholinesterase Inhibitors
Pathological Conditions
Cholinergic Toxidrome
Nicotinic Receptors
Muscarinic Receptors
Nicotinic/Muscarinic Mixture
Signs and Symptoms
Laboratory Tests
Differential Diagnosis
Pediatric Cases
Exposure History
RBC & Serum Tests
Inhibitors & Byproducts
Management Strategies
Secondary Exposure
Supportive Care
First-Line Medications
Medications: Atropine
Medications: Pralidoxime
Antidote Stocking
Deprecated Treatments
Medico-Legal Issues
Intermediate Syndrome
Delayed Neuropathy
Chronic Neurotoxicity
Other Issues
Posttest
Literature Cited
 
Related Documents
 
MMG: Nerve Agents
ToxFAQs™: Nerve Agents
 
Case Studies (CSEM)
 
CSEM Home
Continuing Education
Online Registration
 
ATSDR Resources
 
Case Studies (CSEM)
Exposure Pathways
GATHER (GIS)
Health Assessments
Health Statements
Interaction Profiles
Interactive Learning
Managing Incidents
Medical Guidelines
Minimal Risk Levels
Priority List
ToxFAQs™
ToxFAQs™ CABS
Toxicological Profiles
Toxicology Curriculum
 
External Resources
 
CDC
eLCOSH
EPA
Healthfinder®
Medline Plus
NCEH
NIEHS
NIOSH
OSHA
 

Agency for Toxic Substances and Disease Registry
Case Studies in Environmental Medicine (CSEM) 

Cholinesterase Inhibitors
Including Insecticides and Chemical Warfare Nerve Agents
Part 4: The Cholinergic Toxidrome
Section 11: Management of the Cholinergic Toxidrome
Management Strategy 3: Medications
Diazepam


Learning Objectives

Upon completion of this section, you should be able to

  • Describe why seizure prevention and control is important in the management of the cholinergic toxidrome.
  • Describe the difference in the risk of seizures between adults and pediatric cases of the cholinergic toxidrome.

Misconception

Brain damage from cholinesterase inhibitors reflects a direct toxic effect on neuronal tissue.

Reality

Current thinking is that brain damage results from seizures triggered by cholinesterase inhibitors.


Introduction: Diazepam for Seizures

Incidence of seizures

  • While seizures due to cholinesterase inhibitor toxicity are uncommon in adults, they are common in pediatric cases. (Sofer, Tal et al. 1989; Tareg et al. 2001)
  • They can also be an important problem in adults with high-dose nerve agent intoxication. (Romano, McDonough et al. 2001)
  • The mechanism of convulsion activity is unclear but may involve effects on GABAnergic, glutamanergic, noradrenergic, dopaminergic, and serotonergic systems. (Sidell 1997)

CNS damage appears to be a direct effect of seizure activity

  • Current thinking is that CNS damage from cholinesterase inhibitors is not a direct toxic effect, but is due to seizure activity. (Lotti 1992; Somani, Solana et al. 1992; Sidell 1997; Clegg and van Gemert 1999) At the Workshop on Convulsions and Related Brain Damage Induced by Organophosphorus Agents, held at Aberdeen Proving Ground in Maryland, it was generally agreed that brain lesions did not occur if convulsions lasted less than 45 minutes, and that brain damage was found if convulsions lasted longer than 45 minutes. (Sidell 1997)

Administration of diazepam appears to increase survival and reduce CNS damage in nerve agent poisoning

  • Seizures may not be adequately controlled with atropine and 2-PAM alone. (Schenker, Louie et al. 1998)
  • However, evidence suggests that with significant poisoning, the administration of diazepam is effective, and (even in the absence of seizures) increases survival and reduces CNS damage, and cardiac dysfunction.  (Sidell 1997; Erdman 2004; Wiener and Hoffman 2004)
  • Currently, the administration of diazepam is recommended to treat or prevent these seizures.  (Sidell 1997; Leikin, Thomas et al. 2002; Erdman 2004)

Indications

Current recommendations are for the administration of diazepam for seizures due to nerve agent poisoning and even for severe toxicity (severe respiratory distress or neuromuscular signs) in the absence of seizures. (Sidell 1997; Leikin, Thomas et al. 2002)


Dose  (Sidell 1997; Leikin, Thomas et al. 2002)

Adult

5-10 mg, IV, q 5-10 min (1, 10 mg autoinjector, q10 min x 3 maximum)

Pediatric

0.2 mg/kg, IV, q 5-10 min.


Key Points

  • CNS damage from cholinesterase inhibitor poisoning is currently thought to be due to seizure activity rather than a direct toxic effect.
  • Prevention and treatment of seizures with diazepam is an important aspect of patient management.
  • Seizures are more common in pediatric poisoning with cholinesterase inhibitors.

Progress Check

42. Which of the following statements is true about the use of diazepam for acute cholinesterase inhibitor toxicity? (Choose ALL correct answers)

A. Diazepam is recommended for severe nerve agent poisoning even in the absence of seizures.
B. Current thinking is that CNS damage from acute poisoning with cholinesterase inhibitors is due to seizure activity rather than from a direct toxic effect on brain tissue.
C. The likelihood of seizures in acute cholinesterase inhibitor poisoning is greatest in pediatric cases and in severe cases of nerve agent poisoning.
D. None of the above.

Answer:

To review relevant content, see Introduction in this section.


Previous Section

Next Section

Revised 2007-10-16.